How genetic variation affects patient response and outcome to therapy for psoriasis

References

• Smith CH, Barker JN. Psoriasis and its management. Br. Med. J.333, 380–384 (2006).
   PubMed Web of Science ®Google Scholar
• Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol.4(7), 441–447 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using General Practice Research Database. Eur. Heart J.31, 1000–1006 (2010).
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl. Association of patient-reported psoriasis severity with income and employment. J. Am. Acad. Dermatol.57, 963–971 (2007).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J. Am. Acad. Dermatol.51, 704–708 (2004).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med.361, 496–509 (2009).
   PubMed Web of Science ®Google Scholar
• Capon F, Bijlmakers MJ, Wolf N et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum. Mol. Genet.17, 1938–1945 (2008).
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet.80, 273–290 (2007).
   PubMed Web of Science ®Google Scholar
• Elder JT, Bruce AT, Gudjonsson JE et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol.130, 1213–1226 (2010).
   PubMed Web of Science ®Google Scholar
• Liu Y, Helms C, Liao W et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet.4(3), e1000041 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Huang W, Yang S et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat. Genet.41, 205–210 (2009).
   PubMed Web of Science ®Google Scholar
• Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Acta Dermosifiliogr.100(Suppl. 2), 2–13 (2009).
   PubMedGoogle Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature445, 866–873 (2007).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet370, 263–271 (2007).
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J. Am. Acad. Dermatol.60, 643–659 (2009).
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol.61, 451–485 (2009).
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol.161, 987–1019 (2009).
   PubMed Web of Science ®Google Scholar
• Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol.155, 729–736 (2006).
   PubMed Web of Science ®Google Scholar
• Nijsten T, Margolis D, Feldman SR et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J. Am. Acad. Dermatol.52, 434–444 (2005).
   PubMed Web of Science ®Google Scholar
• Pincelli C, Pignatti M, Borroni RG. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Exp. Dermatol.18, 337–349 (2009).
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol.158, 556–566 (2008).
   Google Scholar
• Heydandael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med.349, 658–665 (2003).
   PubMed Web of Science ®Google Scholar
• Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br. J. Dermatol.159, 513–526 (2008).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ingelman-Sundberg M, Evan WE. Pharmacogenomics and individualised drug therapy. Annu. Rev. Med.57, 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N. Engl. J. Med.348, 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Daly AK. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet.11, 241–246 (2010).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. TPMT testing before azathioprine therapy? Drug Ther. Bull.47(1), 9–12 (2009).
   PubMedGoogle Scholar
• Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q. J. Med.25, 439–444 (2002).
   Google Scholar
• Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J. Am. Acad. Dermatol.55, 369–389 (2006).
   PubMed Web of Science ®Google Scholar
• Anstey AV, Wakelin S, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol.151, 1123–1132 (2004).
   PubMed Web of Science ®Google Scholar
• Fargher EA, Tricker K, Newman W et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin. Pharm. Ther.32, 187–195 (2007).
   PubMed Web of Science ®Google Scholar
• Dubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J. Am. Acad. Dermatol.27, 983–988 (1992).
   PubMed Web of Science ®Google Scholar
• Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J. Am. Acad. Dermatol.32, 67–72 (1995).
   PubMed Web of Science ®Google Scholar
• Halsall JA, Osborne JE, Pringle JH, Hutchinson PE. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet. Genomics15, 349–355 (2005).
   PubMed Web of Science ®Google Scholar
• Holick MF, Chen ML, Kong XF, Sanan DK. Clinical uses for calcitropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology: a new perspective. J. Invest. Dermatol. Symp. Proc.1, 1–9 (1996).
   PubMedGoogle Scholar
• Kontula K, Valimaki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br. J. Dermatol.136, 977–978 (1997).
   PubMed Web of Science ®Google Scholar
• Lee DY, Park PS, Choi KH et al. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Arch. Dermatol. Res.294, 1–5 (2002).
   PubMed Web of Science ®Google Scholar
• Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J. Invest. Dermatol.110, 301–302 (1998).
   PubMed Web of Science ®Google Scholar
• Saeki H, Asano N, Tsunemi Y et al. Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulagaris. J. Dermatol. Sci.30, 167–171 (2002).
   PubMed Web of Science ®Google Scholar
• Roelofzen JH, Aben KK, Oldenhof UT et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J. Invest. Dermatol.130(4), 953–961 (2010).
   PubMed Web of Science ®Google Scholar
• Rojas M, Godschalk R, Alexandrov K et al. Myeloperoxidase-463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients Carcinogenesis22(7), 1015–1018 (2001).
   PubMed Web of Science ®Google Scholar
• Roelofzen JH, Aben KK, van der Valk PG, van Houtum JL, van de Kerkhof PC, Kiemeney LA. Coal tar in dermatology. J. Dermatolog. Treat.18(6), 329–334 (2007).
   PubMed Web of Science ®Google Scholar
• Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J. Invest. Dermatol.127, 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol.128, 1925–1929 (2008).
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br. J. Dermatol.160, 438–441 (2009).
   PubMed Web of Science ®Google Scholar
• Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum.56(6), 1765–1775 (2007).
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br. J. Haematol.146(5), 489–503 (2009).
   PubMed Web of Science ®Google Scholar
• Scionti I, Michelacci F, Pasello M et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann. Oncol.19(8), 1500–1508 (2008).
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum.50(9), 2766–2774 (2004).
   PubMed Web of Science ®Google Scholar
• Press RR, de Fijter JW, Guchelaar HJ. Individualizing calcineurin inhibitor therapy in renal transplantation – current limitations and perspectives. Curr. Pharm. Des.16, 176–186 (2010).
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet.49, 141–175 (2010).
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74(3), 245–254 (2003).
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br. J. Dermatol.162(5), 952–963 (2010).
   PubMed Web of Science ®Google Scholar
• Montrone M, Martorelli D, Rosato A, Dolcetti R. Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. Endocr. Metab. Immune Disord. Drug Targets9(2), 113–131 (2009).
   PubMedGoogle Scholar
• Young HS, Summers AM, Read IR et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J. Invest. Dermatol.126, 453–459 (2006).
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med.180, 1141–1146 (1994).
   PubMed Web of Science ®Google Scholar
• Campalani E, Allen MH, Fairhurst D et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br. J. Dermatol.154, 345–352 (2006).
   PubMed Web of Science ®Google Scholar
• Coto-Segura P, Coto E, Alvarez V et al. Apolipoprotein epsilon4 allele is associated with psoriasis severity. Arch. Dermatol. Res.302(2), 145–149 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med. Klin. (Munich)104, 125–136 (2009).
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol.105(3), 501–523 (2010).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am. J. Gastroenterol.104(2), 465–483 (2009).
   PubMed Web of Science ®Google Scholar
• Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol.113, 401–406 (1998).
   PubMed Web of Science ®Google Scholar
• Li C, Wang G, Gao Y et al. TNF-α gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J. Invest. Dermatol.127, 1886–1892 (2007).
   PubMed Web of Science ®Google Scholar
• Nemec P, Pavkova-Goldbergova M, Stouracova M et al. Polymorphism in the tumor necrosis factor-α gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin. Rheumatol.27, 59–65 (2008).
   PubMed Web of Science ®Google Scholar
• Bansard C, Lequerré T, Daveau M et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology48, 1021–1028 (2009).
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-α-308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J.9, 161–167 (2009).
   PubMed Web of Science ®Google Scholar
• Cui J, Saevarsdottir S, Thomson B et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor a therapy. Arthritis Rheum.62, 1849–1861 (2010).
   PubMed Web of Science ®Google Scholar
• Tan RJ, Gibbons LJ, Potter C et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann. Rheum. Dis.69, 1029–1035 (2010).
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N et al. Fcg receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. Arthritis Rheum.52, 2693–2696 (2005).
   PubMed Web of Science ®Google Scholar
• Potter C, Cordell HJ, Barton A et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways. Ann. Rheum. Dis.69, 1315–1320 (2010).
   PubMed Web of Science ®Google Scholar
• Kooloos WM, Wessels JA, van der Straaten T, Huizinga TW, Guchelaar HJ. Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discov. Today14(17–18), 837–844 (2009).
   PubMed Web of Science ®Google Scholar
• Feng BJ, Sun LD, Soltan-Arabshahi R et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet.5, e1000606 (2009).
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet.41, 199–204 (2009).
   PubMed Web of Science ®Google Scholar
• Koczan D, Drynda S, Hecker M et al. Molecular discrimination of responders and nonresponders to anti-TNF α therapy in rheumatoid arthritis by etanercept. Arthritis Res. Ther.10(3), R50 (2008).
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol.124(5), 1022–1030 (2009).
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, Phase 2 trial. Arch. Dermatol.144, 200–207 (2008).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet371, 1665–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Santos FP, Ravandi F. Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors. Leuk. Lymphoma50 (Suppl. 2), 16–26 (2009).
   PubMed Web of Science ®Google Scholar
• The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360, 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA286(18), 2270–2279 (2001).
   PubMed Web of Science ®Google Scholar
• Asumalahti K, Ameen M, Suomela S et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J. Invest. Dermatol.120(4), 627–632 (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br. J. Dermatol.156(2), 258–262 (2007).
   PubMed Web of Science ®Google Scholar
• Warren RB, Griffiths CE. The potential of pharmacogenetics in optimizing the use of methotrexate in psoriasis. Br. J. Dermatol.153, 869–873 (2005).
   PubMed Web of Science ®Google Scholar